Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL ER vs FLAGYL I.V.
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
Treatment of bacterial vaginosis (FDA-approved),Off-label: Clostridium difficile infection, anaerobic infections, trichomoniasis, amebiasis, giardiasis, rosacea, periodontal disease, Helicobacter pylori eradication
Intra-abdominal infections (e.g., peritonitis, abscess),Pelvic inflammatory disease,Bacterial vaginosis,Surgical prophylaxis,Anaerobic infections (e.g., Clostridium, Bacteroides),Off-label: Helicobacter pylori eradication, rosacea, Crohn's disease
750 mg orally once daily for 10 days for bacterial vaginosis.
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
Hepatic metabolism via side-chain oxidation and glucuronidation; metabolites are 5-nitroimidazoles and hydroxy metabolites; CYP450 enzymes (CYP2A6, CYP3A4, CYP2B6) partially involved.
Hepatic metabolism via oxidation and glucuronidation; major metabolites: hydroxy metabolite (active) and acetic acid metabolite; CYP450 involvement primarily CYP2A6 and CYP3A4.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
<20% (albumin).
Less than 20%, primarily bound to albumin.
0.5-0.8 L/kg; indicates extensive tissue distribution including CNS.
0.5-0.8 L/kg; indicates extensive tissue distribution, including CNS, bone, and abscesses.
Oral: 80-95% (extended-release formulation).
Intravenous: 100%.
No adjustment necessary for GFR >10 m L/min; for GFR <10 m L/min, consider using immediate-release metronidazole instead of FLAGYL ER due to lack of data in severe renal impairment.
No dose adjustment for Cr Cl >10 m L/min. For Cr Cl <10 m L/min, extend interval to every 12 hours. For hemodialysis, administer dose post-dialysis.
Child-Pugh Class A/B: no adjustment necessary. Child-Pugh Class C: reduce dose to 375 mg orally once daily (50% of usual dose).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75%.
Safety and efficacy not established for FLAGYL ER in pediatric patients. Use immediate-release metronidazole for pediatric dosing.
Loading dose: 15 mg/kg IV. Maintenance: 7.5 mg/kg IV every 6 hours. Maximum single dose: 750 mg.
No specific dose adjustment recommended based on age alone; use caution due to potential for decreased renal function and monitor for adverse effects.
Monitor renal function; adjust dose based on Cr Cl. No specific age-related dose reduction.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Avoid chronic use. Reserved for anaerobic and protozoal infections.
Carcinogenicity has been observed in chronic animal studies; avoid chronic use unless necessary.
Peripheral neuropathy (risk with prolonged use), CNS effects (seizures, encephalopathy), disulfiram-like reaction with alcohol, sodium overload (each tablet contains 84 mg sodium), hepatic impairment may increase risk of toxicity, renal impairment (dose adjustment not typically required but monitor), superinfection including C. difficile diarrhea.
Peripheral neuropathy and central nervous system toxicity (e.g., seizures, encephalopathy) with prolonged use; discontinue if neurological symptoms appear; use with caution in hepatic impairment; may cause disulfiram-like reaction with alcohol.
Hypersensitivity to metronidazole or other nitroimidazoles; concurrent use of disulfiram (psychotic reactions); caution in pregnancy (first trimester only if clearly needed; crosses placenta); breastfeeding (use caution due to potential carcinogenicity).
Hypersensitivity to metronidazole or nitroimidazoles; first trimester of pregnancy; concomitant use with disulfiram or alcohol.
Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrups, cooking wine) during therapy and for 48 hours after last dose. No specific food restrictions otherwise.
Avoid alcohol and any products containing ethanol (e.g., cough syrups, mouthwash) during therapy and for at least 48 hours after completion. No specific food restrictions.
Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infections. Trimester 2 and 3: Use with caution; associated with increased risk of cleft lip/palate in some studies; avoid if possible.
Flagyl I. V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Second and third trimesters: Use only if clearly needed; no documented fetal toxicity at usual doses.
Excreted in breast milk; M/P ratio ~0.9; American Academy of Pediatrics considers compatible with breastfeeding, but advise caution; monitor infant for diarrhea or oral thrush.
Metronidazole is excreted in breast milk; M/P ratio approximately 0.9-1.0. Peak milk concentration 2-4 hours after dose. Breastfeeding not recommended during therapy and for 24 hours after the last dose due to potential carcinogenicity and adverse effects in infant.
No specific dose adjustments recommended based on pregnancy pharmacokinetics; however, due to increased GFR in pregnancy, consider monitoring therapeutic levels for severe infections.
No specific dose adjustments required in pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may slightly reduce serum levels but not necessitate dose modification. Use standard adult dosing with caution in severe hepatic impairment.
FLAGYL ER (metronidazole extended-release) is indicated for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy; discontinue if signs occur. Use with caution in hepatic impairment; dose adjustment may be needed. May cause metallic taste.
FLAGYL I. V. (metronidazole) is a nitroimidazole antibiotic with potent anaerobic coverage. It is the drug of choice for Clostridioides difficile infection, but oral vancomycin is preferred for severe cases. IV formulation is used when oral route is not feasible. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). Metronidazole can prolong QT interval; use caution with other QT-prolonging drugs. It is compatible with most IV solutions but avoid mixing with calcium-containing solutions.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablets.,Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Complete the full course even if symptoms improve to ensure infection is fully treated.,Report any numbness, tingling, or pain in hands or feet to your doctor immediately.,Inform your healthcare provider if you have liver disease, a history of blood disorders, or are pregnant or breastfeeding.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, headache, and flushing.,Inform your doctor if you experience numbness or tingling in your hands or feet, as this may indicate nerve damage.,Report any new or worsening symptoms, especially if you have liver disease or are on blood thinners like warfarin (metronidazole can increase INR).,Do not take this medication if you are pregnant without consulting your doctor, especially in the first trimester.,Shake the IV bag gently before use; do not use if the solution is cloudy or contains particles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL ER vs FLAGYL I.V., answered by our medical review team.
FLAGYL ER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.. FLAGYL I.V. is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL ER and FLAGYL I.V. depend on the specific clinical indication. These are both Nitroimidazole Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL ER is: 750 mg orally once daily for 10 days for bacterial vaginosis.. The standard adult dose of FLAGYL I.V. is: 500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL ER and FLAGYL I.V. in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL ER is classified as Category C. Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infec. FLAGYL I.V. is classified as Category C. Flagyl I.V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.